In-home physical frailty monitoring: relevance with respect to clinical tests

Aly Chkeir1, Jean-Luc Novella2, Moustapha Dramé3

  • 1Institut Charles Delaunay, UMR CNRS 6281, Université de Technologie de Troyes (UTT), 12 Rue Marie Curie, CS 42060, F-10004, Troyes, France. aly.chkeir@utt.fr.

BMC Geriatrics
|February 6, 2019
PubMed
Abstract

Related Concept Videos

Area Between Curves: Integrating With Respect to y01:29

Area Between Curves: Integrating With Respect to y

Consider a planar region bounded by two curves that are both written as functions of the vertical variable, y. The left and right boundary curves are continuous between y = c and y = d, and these two horizontal lines define the vertical limits of the region. Because the boundaries depend on y rather than x, the area is most appropriately evaluated using horizontal slices.The area is obtained using the Riemann sum method. The region is divided into many thin horizontal strips, each having an...
51
Area Between Curves: Integrating With Respect to x01:25

Area Between Curves: Integrating With Respect to x

Consider two continuous functions defined on a closed interval from a to b. The region between these curves is bounded vertically by their graphs and horizontally by the endpoints of the interval. The objective is to measure the area of this region.An initial estimate of the area can be obtained by dividing the interval into a large number of narrow vertical strips of equal width. Each strip is approximated by a rectangle whose height is given by the vertical difference between the two...
120
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
217
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
317
Pericarditis II: Clinical Features and Diagnostic Tests01:19

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
321
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
522